This inventor holds 2 USPTO granted patents. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2013-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Yokohama, JP (2013)
- Chiba, JP (2016)
Company Filing History:
Years Active: 2013-2016
Title: Kentaro Takada: Innovator in Cancer Treatment Methods
Introduction
Kentaro Takada is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of cancer treatment through his innovative methods and compounds. With a total of two patents to his name, Takada's work focuses on enhancing the effectiveness of chemotherapeutic agents.
Latest Patents
Takada's latest patents include a method of inhibiting ABCG2 and other treatment methods. These patents disclose methods aimed at enhancing the chemotherapeutic treatment of tumor cells. They also focus on reducing the resistance of cancer cells to chemotherapeutic agents. One of the key methods involves inhibiting ABCG2, Pgp, or MRP1 in mammals afflicted with cancer. Additionally, his patents describe a method for increasing the bioavailability of an ABCG2 substrate drug in mammals. The methods comprise administering effective amounts of specific compounds, which are detailed in the patent documents.
Career Highlights
Kentaro Takada is affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. His work at this prestigious institution has allowed him to contribute to groundbreaking research in cancer treatment.
Collaborations
Takada has collaborated with notable colleagues, including Curtis J. Henrich and Heidi R. Bokesch. These collaborations have further enriched his research and development efforts in the field of oncology.
Conclusion
Kentaro Takada's innovative approaches to cancer treatment exemplify the importance of research and development in medical science. His patents reflect a commitment to improving therapeutic outcomes for cancer patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile